Priority IP Ltd is an independent intellectual property practice based in England operating in alliance with US law firms Kenealy Vaidya LLP and Dunlap Bennet & Ludwig LLP.
Our joint blend of scientific, commercial and litigation skills are used in lasting partnerships with our global clients to build a market focused and robust IP position. We help our global clients not only to obtain patents but we also use our scientific expertise and in-house experience to identify where real value can be enhanced or extracted, whether through IP strategic advice, selective licensing, work-around, collaborations or enforcement.
IP strategy and portfolio management
We can support you with a full range of strategic intellectual property management services.
Irrespective of the size or nature of your enterprise a strategic approach to protecting your ideas is essential.
IP Due Diligence
For us, understanding that the IP due diligence exercise is crucial to the decision-making process is essential to our client's success.
Oppositions and Appeals
Our patent attorney is experienced advocate before the EPO Opposition Divisions and Boards of Appeal.
Find out more
On the 20 July 2020, the Preparatory Committee of the Unified Patent Court (UPC) published UK Withdrawal from the UPCA, stating that “A deposit of the withdrawal notification of ratification has been deposited with the Council Secretariat” after Amanda Solloway (UK IP Minister) parliamentary written statement in the House of Commons.
The UK Supreme Court has overturned a decision from the Court of Appeal to find two of Regeneron’s transgenic mouse EP/UK patents invalid because they were insufficient. This judgement has returned the bar on sufficiency requiring support for practically every embodiment.
The answer is ‘certainly yes‘ – provided, however, the product or formulation is new, inventive and has a technical character.
Although the patent laws of other countries contain similar patentability requirements, few patent offices are as strict in applying this as the EPO. According to the EPO, any amendments to the claims must be directly and unambiguously derivable from the application as originally filed.
We specialise in the Life Sciences and Biotechnology areas.